Abstract
Prostate cancer is the second most frequently diagnosed cancer among men worldwide and a novel treatment for the disease is required. Replication-deficient virus particles, hemagglutinating virus of Japan envelope (HVJ-E), has cytotoxicity to cancer cells. To enhance the therapeutic effect of HVJ-E by photodynamic therapy (PDT) as a trigger of HVJ-E’s anti-tumor effect, talaporfin sodium (Laserphyrin®) used for PDT was encapsulated into HVJ-E to produce a novel photosensitizing drug, named Laserphyrin®-HVJ-E, and its therapeutic effect for prostate cancer cells (PC-3) was evaluated. As the results, direct cytotoxicities of HVJ-E and Laserphyrin®-HVJ-E for PC-3 after an administration time of 48 h were almost the same. Cell survival rates of PC-3, which were irradiated 2 h after administration of Laserphyrin®-HVJ-E, were about 7.8%. Although further study is needed to find an optimal PDT condition, these results suggest that Laserphyrin®-HVJ-E is useful for treatment of prostate cancer due to the combination of cytotoxicities of HVJ-E and PDT.
© 2017 SPIE
PDF ArticleMore Like This
Mizuho Inai, Masaya Yamauchi, Norihiro Honda, Hisanao Hazama, Shoji Tachikawa, Hiroyuki Nakamura, Tomoki Nishida, Hidehiro Yasuda, Yasufumi Kaneda, and Kunio Awazu
OM2D.3 Optical Molecular Probes, Imaging and Drug Delivery (OMP) 2015
A. Petri, M. Kyriazi, E. Alexandratou, M. Rallis, S. Grafe, and D. Yova
7373_1I European Conference on Biomedical Optics (ECBO) 2009
Emel Bakay, Hilal Er, Ayşenur Pamukçu, Didem Şen Karaman, and Nermin Topaloğlu
EW4A.44 European Conference on Biomedical Optics (ECBO) 2021